New drug combo aims to shrink Hard-to-Treat lung tumors
NCT ID NCT03611738
First seen Nov 15, 2025 · Last updated May 15, 2026 · Updated 25 times
Summary
This early-phase study tests a combination of two drugs, ceritinib and docetaxel, in people with advanced non-small cell lung cancer that does not have certain gene changes (ALK-negative, EGFR wild-type). The main goal is to find the safest dose and see if the combination can shrink tumors. About 21 adults who have already tried at least one prior treatment will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advent Health Orlando
Orlando, Florida, 32804, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.